Pearsanta Acquires Adductomics Tech for Cancer Risk Monitoring
Aditxt, Inc. (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, has announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has completed the acquisition of key patents related to adductomics-based DNA damage detection. This acquisition is expected to strengthen Pearsanta’s position in the cancer prevention-focused diagnostic industry by integrating advanced DNA damage analysis into its early detection platform.
Strategic Acquisition and Its Implications
Pearsanta acquired the patents through the issuance of Pearsanta Convertible Preferred Stock, valuing the transaction at approximately $1 million. Over the next two to three years, Pearsanta aims to drive clinical validation, regulatory submissions, and commercialization efforts to fully integrate this technology into its diagnostic portfolio.
The acquisition is aligned with Pearsanta’s mission to enhance early cancer detection and prevention with globally accessible solutions. The company’s proprietary Mitomic® Technology uses mitochondrial DNA biomarkers for non-invasive cancer detection. By adding adductomics-based DNA damage analysis to its platform, Pearsanta expands its ability to assess carcinogen exposure and genomic instability before permanent mutations occur, reinforcing its proactive approach to cancer risk assessment.
Advancing Early Cancer Detection with Adductomics
The acquired patents cover innovative advancements in DNA adduct detection and analysis. DNA adducts—chemical modifications to DNA nucleotides caused by carcinogens—are among the earliest detectable indicators of cancer risk. These modifications result from exposure to environmental toxins and metabolic byproducts, making their detection crucial for understanding an individual’s risk profile.
Pearsanta plans to develop this platform into a comprehensive assessment tool capable of analyzing DNA adducts from urine, blood, or solid tissue samples. This capability will enable researchers and clinicians to identify early indicators of genomic instability and carcinogen exposure, providing a unique opportunity for early intervention before mutations lead to cancer development.
Pathway to Commercialization
Pearsanta is implementing a multi-phase development strategy to bring adductomics-based diagnostics to market. The key components of this strategy include:
- Clinical Validation: Conducting rigorous studies to confirm the technology’s effectiveness in assessing cancer risk.
- Regulatory Submissions: Preparing necessary documentation to integrate the technology into Laboratory Developed Tests (LDTs) and future FDA regulatory pathways.
- Scalability and Market Adoption: Expanding accessibility within CLIA/CAP-certified laboratories to ensure clinical adoption and broad market reach.
By integrating adductomics-based screening into its precision oncology solutions, Pearsanta aims to transition cancer diagnostics from late-stage detection to proactive prevention, offering a transformative approach to early cancer risk assessment.
Redefining Cancer Prevention and Treatment
Current cancer diagnostic methods predominantly detect tumors at later stages, limiting treatment options and increasing costs. Pearsanta’s approach, now enhanced with adductomics technology, represents a paradigm shift toward cancer prevention. By detecting DNA damage at its earliest molecular stages, before irreversible mutations occur, the technology enables personalized preventive measures and early interventions.
Chris Mitton, President of Pearsanta, emphasized the importance of this breakthrough: “We envision a world where cancer risk can be assessed before symptoms appear, giving patients and physicians the opportunity to intervene when it matters most. Pearsanta is uniquely positioned to shift cancer care from reactive treatment to proactive prevention. This advancement has the potential to redefine cancer care by enabling earlier risk assessment, allowing individuals to adjust lifestyle factors, reduce exposure to carcinogens, and adopt personalized prevention strategies.”
Beyond individual patient benefits, early detection and prevention could significantly reduce the overall economic burden of cancer. Detecting DNA damage before disease progression may lower healthcare costs by minimizing reliance on late-stage treatments and hospitalizations. Moreover, in underserved regions where access to advanced oncology treatments remains limited, adductomics-based screening could provide a cost-effective solution for early cancer risk assessment, facilitating timely preventive measures.
The Broader Impact of Aditxt and Pearsanta’s Innovation
Pearsanta’s acquisition of adductomics technology is part of Aditxt’s broader commitment to driving innovation in healthcare and addressing critical global health challenges such as cancer.
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, stated: “Pearsanta’s acquisition reflects Aditxt’s commitment to driving innovation with the potential of addressing some of the most pressing health challenges such as cancer. We believe that this technology has the potential to redefine how we assess and mitigate cancer risk, which could reshape the future of early detection and prevention of cancer.”
Future Prospects
With a focus on integrating adductomics into clinical practice, Pearsanta is set to play a pivotal role in shaping the future of cancer diagnostics. The company’s ongoing research, regulatory initiatives, and commercialization efforts are expected to drive widespread adoption of this technology, potentially making proactive cancer risk assessment a standard component of preventive healthcare.
The acquisition marks a significant step toward realizing the vision of a future where cancer is detected and mitigated before symptoms emerge. As Pearsanta continues its development efforts, its pioneering work in adductomics and precision oncology could lead to groundbreaking advances in cancer prevention, ultimately improving outcomes for millions of individuals worldwide.
